About Micates
The company has 19 employees. Micates offers products and services including Pharmaceutical Analysis and Food Product Analysis.
- Employees 19
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Legal Name Pretty Petals Private Limited
- Date of Incorporation 04 Jan, 2012
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹252 Cr
FY 2025 · +21% YoY
- Net Profit₹6.35 Cr
FY 2025 · 3% margin
- EBITDA₹10.01 Cr
FY 2025 · 4% margin
- Employee Count19
Associated legal entities of Micates
Micates operates through Pretty Petals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pretty Petals Private Limited CIN U51397DL2012PTC229627 | Active | 04 Jan 2012 | New Delhi, Delhi | ₹252 Cr | 19 | 3 | View details |
Products & Services of Micates
Micates offers a comprehensive portfolio of products and services, including Pharmaceutical Analysis and Food Product Analysis.
Pharmaceutical products are analyzed for quality and safety using advanced techniques and experienced personnel.
Food and agricultural products are tested for contaminants and nutritional content in accordance with established guidelines.
Board of directors of Pretty Petals Private Limited (Micates)
Pretty Petals Private Limited is the primary company behind Micates. The board of Pretty Petals Private Limited currently have 3 directors; the longest-serving is Mohinder Paul Jain, appointed in 2012.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mohinder Paul Jain DIN 02666176 | Director | 04 Jan 2012 | 14 yrs 9 mo | Pretty Petals Private Limited |
| Sarla Jain DIN 02666182 | Director | 04 Jan 2012 | 14 yrs 9 mo | Pretty Petals Private Limited |
| Ishendera Jain DIN 06615296 | Director | 30 Jun 2013 | 13 yrs 3 mo | Pretty Petals Private Limited |
Financials of Micates
Figures of Pretty Petals Private Limited, the primary company behind Micates, for FY 2025. Revenue was ₹252 Cr (+21% year on year). Net profit was ₹6.35 Cr (3% margin). EBITDA was ₹10.01 Cr (4% margin). Revenue has grown at a compounded annual rate of -1% over three years and +23% over five years.
- ₹252 CrRevenue · FY 2025 · +21% YoY
- ₹6.35 CrNet profit · 3% margin
- ₹10.01 CrEBITDA · 4% margin
- ₹1.00 CrPaid-up capital
- 19Employees (provident fund records)
- -1%Revenue CAGR, 3 years
- +23%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pretty Petals Private Limited are on its company page.
Detailed financial statements for Micates
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Micates
10 companies that operate in the same segment as Micates (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Micates
Micates has 19 employees.
The primary company behind Micates, Pretty Petals Private Limited, reported revenue of ₹252 Cr for FY 2025, up 21% year on year.
Micates Research and Analysis is operated as the analytical division of Pretty Petals Private Limited, which has interests in healthcare and nutrition. It is equipped with sophisticated instruments and managed by experienced teams to handle testing in pharmaceuticals and food sectors, with expansions planned for petrochemicals and environmental analysis. Services include method validation, stability studies, and microbiological testing, all adhering to international standards. A culture of quality and integrity is maintained, aiming to meet regulatory demands and customer expectations through accurate and timely services across the country.
Micates offers Pharmaceutical Analysis and Food Product Analysis.
Micates operates through Pretty Petals Private Limited.
The legal entities of Micates currently have 3 directors, including Mohinder Paul Jain, Sarla Jain, Ishendera Jain.